Last edition
News about "pirtobrutinib approval"
China Approves Jaypirca for Relapsed CLL and SLL Patients
Jaypirca (pirtobrutinib) by Innovent Biologics has been approved in China for the treatment of adults with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). The BTK inhibitor is designed to overcome resistance associated with prior covalent BTK therapies.
Pirtobrutinib Approval | 02/03/2026 | By News Bureau | 103
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members